These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Economics of reimportation and risks of counterfeit pharmaceuticals. Lybecker KM Manag Care; 2004 Mar; 13(3 Suppl):10-3. PubMed ID: 15074163 [No Abstract] [Full Text] [Related]
3. Australia-United States Free Trade Agreement and the Australian Pharmaceutical Benefits Scheme. Sainsbury P Yale J Health Policy Law Ethics; 2004; 4(2):387-99. PubMed ID: 15536920 [No Abstract] [Full Text] [Related]
4. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies. Hamilton C; Lokuge B; Denniss R Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919 [No Abstract] [Full Text] [Related]
5. Australian trade agreement to start Jan. 1, but battles loom. Med Health; 2004 Dec; 58(43):5-6. PubMed ID: 15612467 [No Abstract] [Full Text] [Related]
6. Counterfeiting and piracy of pharmaceuticals. Grackin A IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698 [No Abstract] [Full Text] [Related]
7. Economic and policy implications of reimportation: a Canadian perspective. Ward C Manag Care; 2004 Mar; 13(3 Suppl):17-20. PubMed ID: 15074165 [No Abstract] [Full Text] [Related]
8. Commerce in drugs and chemicals and the detection of clandestine laboratories. Haislip GR Bull Narc; 1984; 36(1):25-31. PubMed ID: 6564900 [TBL] [Abstract][Full Text] [Related]
9. Canadian drug reimportation debate goes on. Johnson N Drug Discov Today; 2005 May; 10(10):678-9. PubMed ID: 15896676 [No Abstract] [Full Text] [Related]
10. Public policy implications of cross-border Internet pharmacies. Cohen JC Manag Care; 2004 Mar; 13(3 Suppl):14-6. PubMed ID: 15074164 [No Abstract] [Full Text] [Related]
11. Deterring the importation of counterfeit pharmaceutical products. Stearn DW Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351 [No Abstract] [Full Text] [Related]
12. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference. Enzi MB Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090 [No Abstract] [Full Text] [Related]
13. Illegal importation of pharmaceuticals: implications for community pharmacy and public health. Fuller C Manag Care; 2004 Mar; 13(3 Suppl):34-5. PubMed ID: 15074169 [No Abstract] [Full Text] [Related]
14. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical. Kong Y Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580 [TBL] [Abstract][Full Text] [Related]
15. [The Brazilian pharmaceutical industry and foreign trade: is there evidence of regressive specialization?]. Mota FB; Cassiolato JE; Gadelha CA Cad Saude Publica; 2012 Mar; 28(3):527-36. PubMed ID: 22415185 [TBL] [Abstract][Full Text] [Related]
16. 1993 drug dollar volume leaders in hospital pharmacies. Gwinn B Hosp Pharm; 1994 Apr; 29(4):340-4, 362. PubMed ID: 10171823 [No Abstract] [Full Text] [Related]
17. TRIPS, pharmaceuticals, developing countries, and the Doha "solution". Sykes AO Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299 [No Abstract] [Full Text] [Related]
18. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
19. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions. Chodock R; Yolkut D; Connolly DR Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814 [TBL] [Abstract][Full Text] [Related]